RMD vs. DXCM

Last updated Apr 1, 2026

Compare and contrast key facts about ResMed Inc. (RMD) and DexCom, Inc. (DXCM).

Performance

RMD vs. DXCM - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in ResMed Inc. (RMD) and DexCom, Inc. (DXCM). The values are adjusted to include any dividend payments, if applicable.

RMD vs. DXCM - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018	2017
RMD ResMed Inc.	-6.59%	6.26%	34.18%	-16.55%	-19.47%	23.41%	38.33%	37.85%	36.38%	39.06%
DXCM DexCom, Inc.	-5.38%	-14.66%	-37.33%	9.58%	-15.64%	45.23%	69.02%	82.59%	108.75%	-3.87%

Fundamentals

EPS RMD : $15.16 DXCM : $2.07
PE Ratio RMD : 14.81 DXCM : 30.40
PEG Ratio RMD : 0.46 DXCM : 0.72
PS Ratio RMD : 4.08 DXCM : 5.45
Total Revenue (TTM) RMD : $5.40B DXCM : $4.66B
Gross Profit (TTM) RMD : $3.29B DXCM : $2.80B
EBITDA (TTM) RMD : $1.96B DXCM : $1.34B

Returns By Period

In the year-to-date period, RMD achieves a -6.59% return, which is significantly lower than DXCM's -5.38% return. Over the past 10 years, RMD has outperformed DXCM with an annualized return of 15.62%, while DXCM has yielded a comparatively lower 14.02% annualized return.

RMD

• 1D: 2.02%
• 1M: -12.40%
• YTD: -6.59%
• 6M: -17.61%
• 1Y: 1.18%
• 3Y*: 1.78%
• 5Y*: 3.81%
• 10Y*: 15.62%

DXCM

• 1D: 1.45%
• 1M: -14.48%
• YTD: -5.38%
• 6M: -6.67%
• 1Y: -8.04%
• 3Y*: -18.54%
• 5Y*: -7.23%
• 10Y*: 14.02%

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

RMD vs. DXCM — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

RMD

RMD Risk / Return Rank: 41
RMD Sharpe Ratio Rank: 44
RMD Sortino Ratio Rank: 37
RMD Omega Ratio Rank: 36
RMD Calmar Ratio Rank: 45
RMD Martin Ratio Rank: 46

DXCM

DXCM Risk / Return Rank: 34
DXCM Sharpe Ratio Rank: 34
DXCM Sortino Ratio Rank: 31
DXCM Omega Ratio Rank: 32
DXCM Calmar Ratio Rank: 37
DXCM Martin Ratio Rank: 37

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

RMD vs. DXCM - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for ResMed Inc. (RMD) and DexCom, Inc. (DXCM). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	RMD	DXCM	Difference
Sharpe ratio Return per unit of total volatility	0.05	-0.18	+0.23
Sortino ratio Return per unit of downside risk	0.26	0.04	+0.22
Omega ratio Gain probability vs. loss probability	1.03	1.01	+0.03
Calmar ratio Return relative to maximum drawdown	0.12	-0.19	+0.31
Martin ratio Return relative to average drawdown	0.28	-0.38	+0.66
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

RMD vs. DXCM - Sharpe Ratio Comparison

The current RMD Sharpe Ratio is 0.05, which is higher than the DXCM Sharpe Ratio of -0.18. The chart below compares the historical Sharpe Ratios of RMD and DXCM, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	RMD	DXCM	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	0.05	-0.18	+0.23
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	0.12	-0.16	+0.28
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	0.50	0.29	+0.21
Sharpe Ratio (All Time) Calculated using the full available price history	0.53	0.29	+0.25

Correlation

The correlation between RMD and DXCM is 0.33, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Dividends

RMD vs. DXCM - Dividend Comparison

RMD's dividend yield for the trailing twelve months is around 1.04%, while DXCM has not paid dividends to shareholders.

	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
RMD ResMed Inc.	1.04%	0.94%	0.88%	1.07%	0.83%	0.62%	0.73%	0.98%	1.26%	1.61%	2.03%	2.16%
DXCM DexCom, Inc.	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Drawdowns

RMD vs. DXCM - Drawdown Comparison

The maximum RMD drawdown since its inception was -61.61%, smaller than the maximum DXCM drawdown of -94.61%. Use the drawdown chart below to compare losses from any high point for RMD and DXCM.

Drawdown Indicators

	RMD	DXCM	Difference
Max Drawdown Largest peak-to-trough decline	-61.61%	-94.61%	+33.00%
Max Drawdown (1Y) Largest decline over 1 year	-24.74%	-38.75%	+14.01%
Max Drawdown (5Y) Largest decline over 5 years	-53.99%	-66.32%	+12.33%
Max Drawdown (10Y) Largest decline over 10 years	-53.99%	-66.32%	+12.33%
Current Drawdown Current decline from peak	-23.22%	-61.43%	+38.21%
Average Drawdown Average peak-to-trough decline	-15.91%	-35.79%	+19.88%
Ulcer Index Depth and duration of drawdowns from previous peaks	10.55%	19.27%	-8.72%

Volatility

RMD vs. DXCM - Volatility Comparison

The current volatility for ResMed Inc. (RMD) is 6.17%, while DexCom, Inc. (DXCM) has a volatility of 9.22%. This indicates that RMD experiences smaller price fluctuations and is considered to be less risky than DXCM based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	RMD	DXCM	Difference
Volatility (1M) Calculated over the trailing 1-month period	6.17%	9.22%	-3.05%
Volatility (6M) Calculated over the trailing 6-month period	17.04%	27.63%	-10.59%
Volatility (1Y) Calculated over the trailing 1-year period	25.62%	43.67%	-18.05%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	31.07%	46.76%	-15.69%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	31.41%	48.31%	-16.90%

Financials

RMD vs. DXCM - Profitability Comparison

The chart below illustrates the profitability comparison between ResMed Inc. and DexCom, Inc. over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

RMD - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, ResMed Inc. reported a gross profit of 878.72M and revenue of 1.42B. Therefore, the gross margin over that period was 61.8%.

DXCM - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, DexCom, Inc. reported a gross profit of 792.70M and revenue of 1.26B. Therefore, the gross margin over that period was 62.9%.

RMD - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, ResMed Inc. reported an operating income of 491.66M and revenue of 1.42B, resulting in an operating margin of 34.6%.

DXCM - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, DexCom, Inc. reported an operating income of 323.00M and revenue of 1.26B, resulting in an operating margin of 25.6%.

RMD - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, ResMed Inc. reported a net income of 392.59M and revenue of 1.42B, resulting in a net margin of 27.6%.

DXCM - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, DexCom, Inc. reported a net income of 267.30M and revenue of 1.26B, resulting in a net margin of 21.2%.